Presentations day 1

Session: Official opening of BLADDR 2023

• Opening
  Felix Guerrero-Ramos & Xavier Maldonado 

Session: Setting the scene: highlights from major congresses

• NMIBC/MIBC data with an impact on clinical practice
  Bernadett Szabados
• Metastatic UCa data with an impact on clinical practice
  Daan De Maeseneer

Session: Bladder preservation for everyone?

• Misconceptions about TMT
  Valérie Fonteyne
• Health-related QoL after TMT: translation into daily clinical practice
  Deepa Leelamany
• TMT from a patient’s perspective
  Stuart Gaskell
• Panel discussion and Q&A

Session: Optimising the management of NMIBC

• PinPoint Cases
  Panel: Vérane Achard, Ben-Max de Ruiter, Petros Grivas, Felix Guerrero-Ramos, Jacques Irani, Badri Konety, Laura Mertens, Marco Moschini, Fred Witjes
• Treatment advancements for intermediate-risk NMIBC
  Jacques Irani
• How can we improve the quality of tumour resection/ablation?
  Laura Mertens
• High-risk NMIBC beyond RC: the role of RT
  Vérane Achard
  
• Panel discussion and Q&A

Session: Clinical questions: what would you do?

• Risk stratification in NMIBC: are we really doing it the right way?
  Felix Guerrero-Ramos
  
• How do I handle high-risk localised UTUC? The role of perioperative treatment
  Ignacio Duran
• Positive surgical margins after RC for MIBC: what’s next?
  Paul Sargos
• Do men and women with bladder cancer respond differently to treatment?
  Ursula Vogl
• Will intravesical therapies have a role in MIBC and metastatic BCa?
  Fred Witjes
• Final slot:
  • What do I need to know about oncogeriatrics?
  • Physical exercise and cancer: the case of UCa
  • New and future mechanisms of action in mUCa: will we cure our patients in the near future?

Session: NMIBC: evolving towards a multidisciplinary field

• High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies
  Felix Guerrero-Ramos
• The future of NMIBC management
  Felix Guerrero-Ramos & Javier Puente

Session: The diverse treatment landscape of M0 MIBC

• PinPoint Cases
  Panel: Maria De Santis, Ignacio Duran, Valérie Fonteyne, Jacques Irani, Badri Konety, Ekaterina Laukhtina, Xavier Maldonado, Paul Sargos, Bernadett Szabados, Fred Witjes
• The role of RT in bladder preservation
  Xavier Maldonado
• Novel systemic approaches towards bladder preservation
  Ben-Max de Ruiter
• Best practices for RC and urinary reconstruction
  Badrinath Konety
• Perioperative systemic therapies
  Bernadett Szabados
  
• Panel discussion and Q&A

Presentations day 2

Session: The many faces of urinary tract tumours

• Management of upper tract CIS
  Badrinath Konety
• Small cell neuroendocrine carcinoma of the urinary bladder
  Peter Hoskin
• Obstacles and opportunities with staging, grading and molecular classification
  Eva Compérat
• Q&A

Session: Urinary biomarkers for the surveillance of NMIBC

• Debate: Urinary biomarkers for the surveillance of NMIBC
  Marco Moschini & Fred Witjes
• Q&A
  

Session: Multidisciplinary young academics session: future management of a common disease, T2N0M0 UCa

• Pathologist’s perspective
  Alessia Cimadamore
• Medical oncologist’s perspective
  Daniele Raggi
• Radiation oncologist’s perspective
  Paul Sargos
• Urologist’s perspective
  Ekaterina Laukhtina
• Panel discussion and Q&A

Session: Best practices for metastatic UCa

• PinPoint Cases
  Panel: Ananya Choudhury, Daan De Maeseneer, Maria De Santis, Ignacio Duran, Petros Grivas, Peter Hoskin, Rob Jones, Daniele Raggi, Bernadett Szabados, Ursula Vogl
• Targeted therapies on the horizon: all good or should we reconsider?
  Petros Grivas
• How to define and treat OMBC?
  Peter Hoskin
• How to deal with adverse events of targeted therapies?
  Rob Jones
• Panel discussion and Q&A
  Ignacio Duran, Petros Grivas, Rob Jones & Ursula Vogl